Yes, Concerta is a Schedule II Controlled Substance
Concerta (methylphenidate extended-release) is classified as a Schedule II federally controlled substance by the FDA and Drug Enforcement Administration. 1
Regulatory Classification
Concerta contains methylphenidate, which is designated as Schedule II under the Comprehensive Drug Abuse Prevention and Control Act of 1970. 1 This classification is based on the medication's high potential for abuse and the risk that prolonged administration may lead to physical and psychological dependence. 2
Clinical Implications of Schedule II Status
The Schedule II designation carries several important clinical and regulatory considerations:
Black Box Warnings
- High abuse potential: Methylphenidate has a black box warning stating it should be given cautiously to patients with a history of drug dependence or alcoholism 2
- Risk of substance use disorder: Misuse and abuse can lead to the development of addiction, and the medication can be diverted for non-medical use 1
Abuse and Diversion Risks
While Concerta has abuse potential, its extended-release formulation offers some protective features compared to immediate-release methylphenidate:
- The medication is formulated as a paste within the caplet that cannot be easily ground up or snorted 3
- Once-daily dosing reduces the need to bring medication to school, decreasing opportunities for diversion 3
- Studies show Concerta produces lower subjective abuse-related responses compared to immediate-release methylphenidate at equivalent doses 1
Prescribing Requirements
As a Schedule II medication, Concerta requires:
- Careful documentation and dispensing records
- Storage in locked cabinets in institutional settings 3
- Assessment of patient and family history of substance abuse before prescribing 3
- Regular monitoring during treatment 1
Comparison to Other ADHD Medications
For context, other ADHD medications have different scheduling:
- Schedule II: All amphetamine products (dextroamphetamine, lisdexamfetamine), all methylphenidate formulations including Concerta 2, 4
- Schedule III: Hydrocodone combination products (not used for ADHD) 4
- Schedule IV: Modafinil and armodafinil 2
- Non-scheduled: Atomoxetine, guanfacine, clonidine 5
The Schedule II classification reflects methylphenidate's pharmacological properties and abuse liability, requiring heightened prescriber vigilance and regulatory oversight, but does not preclude its use as an effective first-line treatment for ADHD when appropriately prescribed and monitored.